These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 22773165)

  • 1. D₂-receptor occupancy measurement of JNJ-37822681, a novel fast off-rate D₂-receptor antagonist, in healthy subjects using positron emission tomography: single dose versus steady state and dose selection.
    Schmidt ME; de Boer P; Andrews R; Neyens M; Rossenu S; William Falteos D; Mannaert E
    Psychopharmacology (Berl); 2012 Dec; 224(4):549-57. PubMed ID: 22773165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetics of JNJ-37822681, a selective fast-dissociating dopamine D₂-receptor antagonist, in healthy subjects and subjects with schizophrenia and dose selection based on simulated D₂-receptor occupancy.
    Hoeben E; Neyens M; Mannaert E; Schmidt M; Vermeulen A
    Clin Pharmacokinet; 2013 Nov; 52(11):1005-15. PubMed ID: 23754735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Striatal and extrastriatal D2/D3-receptor-binding properties of ziprasidone: a positron emission tomography study with [18F]Fallypride and [11C]raclopride (D2/D3-receptor occupancy of ziprasidone).
    Vernaleken I; Fellows C; Janouschek H; Bröcheler A; Veselinovic T; Landvogt C; Boy C; Buchholz HG; Spreckelmeyer K; Bartenstein P; Cumming P; Hiemke C; Rösch F; Schäfer W; Wong DF; Gründer G
    J Clin Psychopharmacol; 2008 Dec; 28(6):608-17. PubMed ID: 19011428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo quantification of striatal dopamine D2 receptor occupancy by JNJ-37822681 using [11C]raclopride and positron emission tomography.
    te Beek ET; de Boer P; Moerland M; Schmidt ME; Hoetjes NJ; Windhorst AD; van Berckel BN; Cohen AF; van Gerven JM; Lammertsma AA
    J Psychopharmacol; 2012 Aug; 26(8):1128-35. PubMed ID: 22290934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dopamine D2 receptor occupancy by perospirone: a positron emission tomography study in patients with schizophrenia and healthy subjects.
    Arakawa R; Ito H; Takano A; Okumura M; Takahashi H; Takano H; Okubo Y; Suhara T
    Psychopharmacology (Berl); 2010 May; 209(4):285-90. PubMed ID: 20349050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A double-blind, randomized, placebo-controlled study with JNJ-37822681, a novel, highly selective, fast dissociating D₂ receptor antagonist in the treatment of acute exacerbation of schizophrenia.
    Schmidt ME; Kent JM; Daly E; Janssens L; Van Osselaer N; Hüsken G; Anghelescu IG; Van Nueten L
    Eur Neuropsychopharmacol; 2012 Oct; 22(10):721-33. PubMed ID: 22464973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Striatal and extrastriatal dopamine D2 receptor occupancy by a novel antipsychotic, blonanserin: a PET study with [11C]raclopride and [11C]FLB 457 in schizophrenia.
    Tateno A; Arakawa R; Okumura M; Fukuta H; Honjo K; Ishihara K; Nakamura H; Kumita S; Okubo Y
    J Clin Psychopharmacol; 2013 Apr; 33(2):162-9. PubMed ID: 23422369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dopamine D₂/₃ occupancy of ziprasidone across a day: a within-subject PET study.
    Suzuki T; Graff-Guerrero A; Uchida H; Remington G; Caravaggio F; Borlido C; Pollock B; Mulsant B; Deluca V; Ismail Z; Mamo D
    Psychopharmacology (Berl); 2013 Jul; 228(1):43-51. PubMed ID: 23417515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual time-point imaging for post-dose binding potential estimation applied to a [
    Lopes Alves I; Willemsen AT; Dierckx RA; da Silva AM; Koole M
    J Cereb Blood Flow Metab; 2017 Mar; 37(3):866-876. PubMed ID: 27073203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modeling of brain D2 receptor occupancy-plasma concentration relationships with a novel antipsychotic, YKP1358, using serial PET scans in healthy volunteers.
    Lim KS; Kwon JS; Jang IJ; Jeong JM; Lee JS; Kim HW; Kang WJ; Kim JR; Cho JY; Kim E; Yoo SY; Shin SG; Yu KS
    Clin Pharmacol Ther; 2007 Feb; 81(2):252-8. PubMed ID: 17259948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of risperidone on high-affinity state of dopamine D2 receptors: a PET study with agonist ligand [11C](R)-2-CH3O-N-n-propylnorapomorphine.
    Kodaka F; Ito H; Takano H; Takahashi H; Arakawa R; Miyoshi M; Okumura M; Otsuka T; Nakayama K; Halldin C; Farde L; Suhara T
    Int J Neuropsychopharmacol; 2011 Feb; 14(1):83-9. PubMed ID: 20860881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of healthy volunteers instead of patients to inform drug dosing studies: a [¹¹C]raclopride PET study.
    Kim E; Howes OD; Kim BH; Yu KS; Jeong JM; Lee JS; Kim SJ; Jang IJ; Park JS; Kim YG; Shin SG; Turkheimer FE; Kapur S; Kwon JS
    Psychopharmacology (Berl); 2011 Oct; 217(4):515-23. PubMed ID: 21503604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Striatal Dopamine D2 Receptor Occupancy Induced by Daily Application of Blonanserin Transdermal Patches: Phase II Study in Japanese Patients With Schizophrenia.
    Nishibe H; Tateno A; Sakayori T; Yamamoto M; Kim W; Kakuyama H; Okubo Y
    Int J Neuropsychopharmacol; 2021 Feb; 24(2):108-117. PubMed ID: 32936897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Binding of the D3-preferring antipsychotic candidate F17464 to dopamine D3 and D2 receptors: a PET study in healthy subjects with [
    Slifstein M; Abi-Dargham A; Girgis RR; Suckow RF; Cooper TB; Divgi CR; Sokoloff P; Leriche L; Carberry P; Oya S; Joseph SK; Guiraud M; Montagne A; Brunner V; Gaudoux F; Tonner F
    Psychopharmacology (Berl); 2020 Feb; 237(2):519-527. PubMed ID: 31773210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and central nervous system effects of the novel dopamine D2 receptor antagonist JNJ-37822681.
    te Beek ET; Moerland M; de Boer P; van Nueten L; de Kam ML; Burggraaf J; Cohen AF; van Gerven JM
    J Psychopharmacol; 2012 Aug; 26(8):1119-27. PubMed ID: 21890591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimating dopamine D₂ receptor occupancy for doses of 8 antipsychotics: a meta-analysis.
    Lako IM; van den Heuvel ER; Knegtering H; Bruggeman R; Taxis K
    J Clin Psychopharmacol; 2013 Oct; 33(5):675-81. PubMed ID: 23948784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does early improvement predict response to the fast-dissociating D₂ receptor antagonist JNJ-37822681 in patients with acute schizophrenia?
    Anghelescu IG; Janssens L; Kent J; de Boer P; Tritsmans L; Daly EJ; van Nueten L; Schmidt ME
    Eur Neuropsychopharmacol; 2013 Sep; 23(9):1043-50. PubMed ID: 22995972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia.
    Arakawa R; Ito H; Takano A; Takahashi H; Morimoto T; Sassa T; Ohta K; Kato M; Okubo Y; Suhara T
    Psychopharmacology (Berl); 2008 Apr; 197(2):229-35. PubMed ID: 18058087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurovascular coupling to D2/D3 dopamine receptor occupancy using simultaneous PET/functional MRI.
    Sander CY; Hooker JM; Catana C; Normandin MD; Alpert NM; Knudsen GM; Vanduffel W; Rosen BR; Mandeville JB
    Proc Natl Acad Sci U S A; 2013 Jul; 110(27):11169-74. PubMed ID: 23723346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, pharmacokinetic, and positron emission tomography evaluation of serotonin and dopamine transporter occupancy following multiple-dose administration of the triple monoamine reuptake inhibitor BMS-820836.
    Zheng M; Appel L; Luo F; Lane R; Burt D; Risinger R; Antoni G; Cahir M; Keswani S; Hayes W; Bhagwagar Z
    Psychopharmacology (Berl); 2015 Feb; 232(3):529-40. PubMed ID: 25116481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.